Published in Diabetes on April 01, 2004
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest (2006) 3.41
Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine (2008) 1.30
Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria. Kidney Int (2010) 1.22
Hepatocyte growth factor family negatively regulates hepatic gluconeogenesis via induction of orphan nuclear receptor small heterodimer partner in primary hepatocytes. J Biol Chem (2009) 1.20
Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol (2014) 0.91
Endothelin and the podocyte. Clin Kidney J (2012) 0.85
A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr Med Chem (2014) 0.84
Signal transduction in podocytes--spotlight on receptor tyrosine kinases. Nat Rev Nephrol (2014) 0.82
Diabetes Induces Aberrant DNA Methylation in the Proximal Tubules of the Kidney. J Am Soc Nephrol (2015) 0.81
The selected traditional chinese medicinal formulas for treating diabetic nephropathy: perspective of modern science. J Tradit Complement Med (2013) 0.79
Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes. Diabetologia (2012) 0.79
Virus integration and genome influence in approaches to stem cell based therapy for andro-urology. Adv Drug Deliv Rev (2014) 0.77
Animal models of regression/progression of kidney disease. Drug Discov Today Dis Models (2014) 0.77
A tandem repeat of a fragment of Listeria monocytogenes internalin B protein induces cell survival and proliferation. Am J Physiol Lung Cell Mol Physiol (2010) 0.75
Steap4 attenuates high glucose and S100B-induced effects in mesangial cells. J Cell Mol Med (2015) 0.75
Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med (2007) 9.44
Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell (2012) 2.45
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
Correlation between the protein/creatinine ratio in spot urine and 24-hour urine protein. Nefrologia (2012) 1.97
Centrosome overduplication and mitotic instability in PKD2 transgenic lines. Cell Biol Int (2008) 1.89
Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol (2006) 1.79
CD40: an upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling. Blood (2008) 1.56
Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int (2013) 1.54
Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation (2012) 1.52
X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood (2010) 1.51
DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am J Hum Genet (2008) 1.45
The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation (2004) 1.44
Low serum mannose-binding lectin as a risk factor for new onset diabetes mellitus after renal transplantation. Transplantation (2009) 1.44
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome. Exp Neurol (2012) 1.40
Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression. Transpl Int (2008) 1.37
An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia (2013) 1.37
Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol (2006) 1.17
Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol (2008) 1.15
Epigenetic disruption of cadherin-11 in human cancer metastasis. J Pathol (2012) 1.14
Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev (2012) 1.11
Estimation of total glomerular number in stable renal transplants. J Am Soc Nephrol (2003) 1.10
Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment. FASEB J (2002) 1.10
Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol (2007) 1.08
Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci U S A (2012) 1.06
Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia (2009) 1.06
Clinicopathological and molecular characterization of colorectal micropapillary carcinoma. Mod Pathol (2011) 1.05
BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics (2012) 1.05
Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol (2008) 1.04
Promising effects of ischemic preconditioning in renal transplantation. Kidney Int (2002) 1.03
Do alloreactivity and prolonged cold ischemia cause different elementary lesions in chronic allograft nephropathy? Am J Pathol (2003) 1.02
Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int (2002) 0.99
Ischemic preconditioning in solid organ transplantation: from experimental to clinics. Transpl Int (2007) 0.99
Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol (2010) 0.98
Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol Dial Transplant (2009) 0.97
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling. Cell Stem Cell (2010) 0.97
Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res (2009) 0.96
CD40 gene silencing reduces the progression of experimental lupus nephritis modulating local milieu and systemic mechanisms. PLoS One (2013) 0.93
Belatacept: from rational design to clinical application. Transpl Int (2011) 0.93
Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials. Transplantation (2013) 0.93
Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl Int (2011) 0.92
Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol (2013) 0.92
Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Int J Cancer (2012) 0.91
The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol (2012) 0.91
Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant (2007) 0.90
Non-invasive bioluminescence imaging for monitoring herpes simplex virus type 1 hematogenous infection. Microbes Infect (2006) 0.90
Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant (2008) 0.90
Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS One (2012) 0.90
Transcription factors Sp1 and p73 control the expression of the proapoptotic protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin. J Biol Chem (2012) 0.90
Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiol Dis (2006) 0.90
Behavioral characterization of a mouse model overexpressing DSCR1/ RCAN1. PLoS One (2011) 0.89
New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy. Exp Diabetes Res (2012) 0.89
RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood (2004) 0.89
Renal involvement in non-malignant IgM gammopathy. Nephrol Dial Transplant (2006) 0.89
Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts. Oncotarget (2013) 0.89
Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype. Mol Carcinog (2011) 0.88
Overexpression of PKD2 in the mouse is associated with renal tubulopathy. Nephrol Dial Transplant (2007) 0.88
Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis (2012) 0.87
Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. Nephrol Dial Transplant (2011) 0.87
Glycolytic pyruvate regulates P-Glycoprotein expression in multicellular tumor spheroids via modulation of the intracellular redox state. J Cell Biochem (2010) 0.87
Misleading gene conversion frequencies due to a PCR artifact using small fragment homologous replacement. Oligonucleotides (2003) 0.87
Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett (2011) 0.87
Biomarkers in renal transplantation. Curr Opin Organ Transplant (2010) 0.87
Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation (2004) 0.86
Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Transpl Int (2012) 0.86
The quail mesonephros: a new model for renal senescence? J Vasc Res (2006) 0.86
Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing. PLoS One (2011) 0.86
Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. Am J Hum Genet (2008) 0.86
Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors. Oncology (2005) 0.86
Connexin-26 is a key factor mediating gemcitabine bystander effect. Mol Cancer Ther (2011) 0.85